Eligo Bioscience logoEB

Eligo Bioscience

Verified

Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals. Healthcare Biotech

About Eligo Bioscience

Eligo Bioscience is tracked on 100Xfounder as a healthcare company, founded in 2014, based in Paris, France, currently mapped to the Series A stage. Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals. Healthcare Biotech

Profile snapshot: Founders linked: Eligo Bioscience Team. Funding tracked: $23.00M. Hiring focus: Open Roles. Tech tags: Python, GCP, BigQuery, and React.

Recent signals:

  • Eligo Bioscience appears in the 100Xfounder startup directory import feed.

Why it Matters

Eligo Bioscience is worth tracking because its funding history is already mapped here, including a $23.00M round, the hiring signal points to active work across Open Roles roles, recent coverage is already tied back to this page, and Eligo Bioscience Team's founder profile is linked directly from the company page. Use this page as the starting point before moving into the company news hub, founder profiles, and related market pages.

Funding Snapshot

Total Funding: $23.00MLast Round: Series A Khosla Ventures, $23M Series A in 2020All Rounds: 1
  • Series A | Khosla Ventures, $23M Series A in 2020

Hiring Roles

This company is actively hiring.

Open Roles

Meet the Founders

Tech Stack

PythonGCPBigQueryReact

Last updated: June 1, 2026

Eligo Bioscience research snapshot

This page is assembled from the published company profile, linked founder directory records, and tagged newsroom context already stored on 100Xfounder. It is most useful as a quick starting point before moving into the deeper company, founder, and hub routes below.

  • Company summary

    Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals. Healthcare Biotech

  • Founders covered

    Eligo Bioscience Team

  • Market position

    Healthcare | Series A | Paris, France

  • Newsroom signal

    No direct company-tagged stories are mapped yet; use the connected hubs below for broader market context.

  • Funding signal

    $23.00M

Best next clicks

Start with the lead founder profile if you want operator context first, then return to the company news hub for chronology.

Related Companies

Alternatives in Healthcare with comparable market signals.

Discover Now

Newsroom and topic pages connected to Eligo Bioscience.

No company-specific newsroom stories available yet.

Contextual Research Links

Jump to country, industry, stage, startup taxonomy, and newsroom routes tied to this company.

Want to get featured on 100Xfounder?

Want your company featured with founder details and funding visibility? Start here.

FAQs About Eligo Bioscience

Common questions people ask about this profile.

What is Eligo Bioscience?

Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals. Healthcare Biotech

Who founded Eligo Bioscience?

Eligo Bioscience is associated with Eligo Bioscience Team on 100Xfounder.

Where is Eligo Bioscience located?

Eligo Bioscience is listed in Paris, France.

What stage is Eligo Bioscience in?

Eligo Bioscience is currently mapped to Series A. Funding context: Khosla Ventures, $23M Series A in 2020

What is the latest funding round of Eligo Bioscience?

Eligo Bioscience's latest tracked round is Series A Khosla Ventures, $23M Series A in 2020. Total tracked rounds: 1.

Is Eligo Bioscience hiring now?

Eligo Bioscience hiring status: Open Roles.

What technologies does Eligo Bioscience use?

Eligo Bioscience is associated with Python, GCP, BigQuery, and React.

Is Eligo Bioscience verified on 100Xfounder?

Yes. Eligo Bioscience is currently marked verified on 100Xfounder as of June 1, 2026.

How can users connect with Eligo Bioscience founders?

Users can move from the company page to any linked founder profiles, review the company news hub, and use listed company links when public contact routes are available.